CAR-NK constructs containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain offer improved NK cell-mediated killing of tumor cells (114). This evidence concerns the gene KLRK1 and neoplasm.